BX471 is primarily researched for its potential therapeutic applications, particularly in the field of immunology and inflammatory diseases. It functions as a selective antagonist of the CCR1 chemokine receptor, which plays a significant role in the migration of immune cells to sites of inflammation. By blocking CCR1, BX471 has shown promise in reducing inflammatory responses in preclinical studies, making it a candidate for treating conditions such as multiple sclerosis, rheumatoid arthritis, and other autoimmune disorders. Additionally, its ability to modulate immune cell trafficking has sparked interest in its potential use in organ transplantation to prevent graft rejection. Further research is ongoing to explore its efficacy and safety in clinical settings.